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Psychological treatments are increasingly regarded as useful interventions for schizophrenia. 
However, a comprehensive evaluation of the available evidence is lacking and the benefit of 
psychological interventions for patients with current positive symptoms is still debated. The 
present study aimed to evaluate the efficacy, acceptability and tolerability of psychological 
treatments for positive symptoms of schizophrenia by applying a network meta-analysis 
approach, that can integrate direct and indirect comparisons. We searched EMBASE, 
MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Library, World Health Organization’s 
International Clinical Trials Registry Platform and ClinicalTrials.gov for randomized controlled 
trials of psychological treatments for positive symptoms of schizophrenia, published up to 
January 10, 2018. We included studies on adults with a diagnosis of schizophrenia or a 
related disorder presenting positive symptoms. The primary outcome was change in positive 
symptoms measured with validated rating scales. We included 53 randomized controlled 
trials of seven psychological interventions, for a total of 4,068 participants receiving the 
psychological treatment as add-on to antipsychotics. On average, patients were moderately 
ill at baseline. The network meta-analysis showed that cognitive behavioural therapy (40 
studies) reduced positive symptoms more than inactive control (standardized mean 
difference, SMD=–0.29; 95% CI: –0.55 to –0.03), treatment as usual (SMD=–0.30; 95% CI: –
0.45 to –0.14) and supportive therapy (SMD=–0.47; 95% CI: –0.91 to –0.03). Cognitive 
behavioural therapy was associated with a higher dropout rate compared with treatment as 
usual (risk ratio, RR=0.74; 95% CI: 0.58 to 0.95). Confidence in the estimates ranged from 
moderate to very low. The other treatments contributed to the network with a lower number 
of studies. Results were overall consistent in sensitivity analyses controlling for several 
factors, including the role of researchers’ allegiance and blinding of outcome assessor. 
Cognitive behavior therapy seems to be effective on positive symptoms in moderately ill 
patients with schizophrenia, with effect sizes in the lower to medium range, depending on the 
control condition.  
Key words: Schizophrenia, positive symptoms, psychological interventions, cognitive 
behavioural therapy, network meta-analysis 
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Psychological interventions for schizophrenia have been developed to address many 
aspects of the disorder and, according to guidelines from the National Institute for Health and 
Care Excellence (NICE)1 in the UK and the Schizophrenia Patient Outcomes Research Team 
(PORT)2 in the US, are regarded as useful interventions.  
A number of systematic reviews of randomized studies have been conducted on these 
treatments3. However, findings are unclear and often contradictory. For example, while some 
reviews4,5 have found a superiority of cognitive behavioural therapy (CBT) compared to usual 
care, other authors could not replicate this finding when non-blinded randomized controlled 
trials (RCTs) were excluded6. A Cochrane review found CBT to be effective in the long term, 
but not in the short or medium term7, while another meta-analysis did not find a benefit for 
CBT8.  
Moreover, the current evidence presents several shortcomings. First, all the existing 
reviews have compared two interventions at a time using pairwise meta-analysis. This 
method summarizes results only when two treatments have already been compared in 
existing studies, leaving open questions for all the other possible comparisons. Even in the 
review by Turner et al9, which included only studies comparing two “active psychological 
interventions”, pairwise meta-analysis was applied to compare each intervention with the 
pooled others, again not providing information on the comparisons that were not already 
considered in a trial.   
Furthermore, the existing reviews have included heterogeneous samples, pooling 
patients with different sets of symptoms. No review focused specifically on patients with 
current positive symptoms, which are – at least in the acute phase – at the core of the 
disorder. Also the review by Zimmermann et al5, aiming at evaluating the effect of CBT on 
positive symptoms, did not restrict its selection to studies on patients presenting these 
symptoms.  
As a result of these limitations in the current evidence, it is still unclear whether there are 
efficacious and acceptable psychological interventions for treating positive symptoms in 
schizophrenia.  
The aim of the present study was to overcome these limitations by conducting a network 
meta-analysis, which integrates direct and indirect comparisons of interventions10, and 
informs about differences between treatments, even when direct comparisons are not 
available. Such a meta-analysis requires a certain degree of homogeneity in the population, 
settings and methods across the studies. A careful definition of the target population of the 
intervention is therefore essential in order to produce information that is useful for clinical 
practice.  
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Our network meta-analysis covered psychological interventions addressing positive 
symptoms of schizophrenia, in patients currently experiencing such symptoms, in order to 
generate results that will be relevant for this specific population.   
 
 
METHODS  
 
Study design and participants 
 
The detailed methodology for this systematic review and network meta-analysis is 
described in the study protocol, that was registered a priori at PROSPERO (no. 
CRD42017067795) and published3. In reporting results, we followed the PRISMA extension 
statement for network meta-analyses11,12.  
We included studies in adult individuals with a diagnosis of schizophrenia or a related 
disorder (such as schizophreniform or schizoaffective disorder), presenting active positive 
symptoms, or in the phase of acute exacerbation, as defined by inclusion criteria of the trial, 
without restrictions on setting, gender or ethnicity. We optimized homogeneity of studies 
within and across treatment comparisons by excluding studies on patients with predominant 
negative symptoms or concomitant medical or psychiatric illness, and patients in their first 
psychotic episode or at risk of psychosis. Studies were included if at least 80% of the 
patients had schizophrenia or related disorders. In case of a mixed population, data about 
patients with schizophrenia were extracted, if available. We included the trials irrespective of 
the diagnostic criteria used.  
 
Interventions and comparators 
 
As defined a priori in our protocol3, interventions were any psychological treatments that 
occur through an interaction between therapist and patient, either face-to-face individually or 
in group, with the primary aim to reduce positive symptoms. 
Comparators were classified as follows: a) interventions (e.g., cognitive remediation, 
psychoeducation) with a primary target different from improving positive symptoms (e.g., 
cognition, knowledge of the illness, adherence to medication, functioning), which were 
primarily analyzed as separate nodes, then combined in a sensitivity analysis; b) inactive 
controls, defined as interventions intended to control for non-specific aspects of the therapy 
(befriending, recreation and support, social activity therapy, supportive counselling), also 
sometimes referred to as “psychological placebos”; c) treatment as usual (i.e., patients 
continue to receive standard psychiatric care); d) waiting list.  
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Outcomes 
 
The primary outcome was the change in positive symptoms of schizophrenia, as 
measured by a rating scale such as the positive subscale of the Positive and Negative 
Syndrome Scale (PANSS)13, the positive subscale of the Brief Psychiatric Rating Scale 
(BPRS)14, or any other published scale.  
Secondary outcomes were: study dropout for any reason (all-cause discontinuation), 
effects on overall symptoms of schizophrenia, effects on negative symptoms, response (as 
defined in the study), relapse (operationalized by rating scales or, if not available, 
rehospitalization due to psychopathology), adherence and insight, changes in depressive 
symptoms, quality of life, functioning, adverse events that might be related to psychological 
treatment (according to Linden et al15), and mortality (measured as death for any reason, 
death due to natural causes, death due to suicide). All outcomes were measured at study 
endpoint, as defined in each study.  
 
Search strategy and selection criteria 
 
We searched EMBASE, MEDLINE, PsycINFO, PubMed, BIOSIS, Cochrane Library, 
World Health Organization’s International Clinical Trials Registry Platform and 
ClinicalTrials.gov for RCTs published up to January 10, 2018, comparing psychological 
interventions with each other or with a non-pharmacological control condition in people with 
schizophrenia who presented active positive symptoms. Additionally, we searched the 
reference lists of previous reviews.  
We applied no language restrictions, with the exception that we did not search Chinese 
databases. We contacted authors of included studies published in the last 30 years for 
missing or additional information about their studies.  
 
Data extraction and risk of bias assessment 
 
All abstracts identified by the search were reviewed independently by two researchers of 
the group. Disagreements were resolved by discussion, and in case of doubts the full paper 
was retrieved for further inspection. Full reports were obtained for all eligible papers, and 
again assessed by two independent reviewers. Disagreements were discussed with the 
senior author and, in case of need, study authors were contacted for further information. 
Two researchers independently extracted data from the selected studies, considering 
main reports and supplementary materials, entered the relevant information into a Microsoft 
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Access database especially created for this study, and assessed risk of bias using the 
Cochrane risk of bias tool16. The following domains of possible bias were considered: 
sequence generation, allocation concealment, blinding of participants, blinding of outcome 
assessors, incomplete outcome data, selective reporting, researchers’ allegiance17,18, other 
bias. We also made a global risk of bias rating for each study based on criteria applied in a 
network meta-analysis of antidepressants19.  
 
Statistical analysis 
 
We performed random effects pairwise meta-analyses and network meta-analysis in a 
frequentist framework using the netmeta package in R (version 3.4.3)20,21. We calculated 
standardized mean differences (SMDs) for continuous outcomes, and risk ratios (RRs) for 
binary outcomes, both presented with their 95% confidence intervals (CIs). We also 
calculated the relative ranking for each intervention using the Surface Under the Cumulative 
Ranking curve (SUCRA), estimated within the frequentist framework (as P scores)22.  
Before running the network meta-analysis, we attempted to assess the transitivity 
assumption. This assumption implies that studies comparing different sets of interventions 
are sufficiently similar to provide valid indirect inferences, which we tried to ensure by 
applying narrow inclusion criteria and making populations as similar as possible within and 
across treatment comparisons. We also considered whether the potential effect modifiers 
(listed below) were distributed similarly across the available direct comparisons.  
We assumed a common heterogeneity parameter across the various treatment 
comparisons, and presented the between study variance (tau²) for each outcome. We 
characterized the amount of heterogeneity as low, moderate or high, using the first and third 
quantiles of their empirical distributions23. Statistical inconsistency was evaluated separating 
direct evidence from indirect evidence provided by the entire network, and then testing the 
agreement of these two pieces of evidence24. The magnitude of inconsistency factors (the 
difference in direct and indirect SMD) and their respective p values were used to identify the 
presence of inconsistency. We also applied the design-by-treatment interaction model, that 
evaluates inconsistency in the network jointly25.  
To explore potential sources of heterogeneity or inconsistency, we planned a priori 
subgroup analyses for the primary outcome on the following potential effect modifiers: 
number of sessions, study duration, setting (individual vs. group), expertise of the therapist, 
baseline severity. Sensitivity analyses were performed excluding open label studies, studies 
that presented only completer analyses, studies at overall high risk of bias19, studies with 
high risk of researchers’ allegiance, studies focused on treatment-resistant patients, and 
studies with a non-active comparison group. We also assessed small trial effects (potentially 
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associated with publication bias) by examining funnel plots of pairwise meta-analyses and 
comparison-adjusted funnel plots, if ten or more studies were included26. Additionally, we 
assessed the confidence in estimates of the main outcome with Confidence in Network Meta-
Analysis (CINeMA), an adaptation of the Grading of Recommendations Assessment, 
Development and Evaluation framework (GRADE) specifically developed for network meta-
analysis27. 
 
 
RESULTS  
 
Characteristics of included studies 
 
21,772 references were identified by the search (last update January 10, 2018), and 
2,754 articles were retrieved in full text (Figure 1). We included 62 randomized controlled 
trials, of which 53 had usable data and were included in the network meta-analysis (involving 
4,068 participants) (Table 1).  
These trials provided comparisons of the following psychological treatments: CBT 
(N=40)28-67, metacognitive training (N=6)68-73, mindfulness (N=2)74,75, acceptance and 
commitment therapy (N=2)76,77, experience focused counselling (N=1)78, hallucination 
focused integrative treatment (N=1)79, and AVATAR therapy (N=1)80.  
The mean sample size was 76.5 participants (range 6-218), and the median trial duration 
was 13 weeks (range 4-44 weeks). Of 3,941 participants whose gender was reported, 2,361 
were men (59.9%). The mean duration of illness was 12.4 years, and the mean age of 
participants was 37.4 years. Nine studies included only inpatients, 15 only outpatients and 14 
both, while 15 did not provide information on patients’ status. On average, patients had 
moderate schizophrenic symptoms, with a mean reported PANSS baseline score of 
68.2681,82. Thanks to collaboration of the authors, we were able to include unpublished data 
for some studies36,37,41-43,57,61,68,72. 
 
Risk of bias assessment 
 
Six, 27 and 21 of the included studies were considered to be at low, moderate and high 
overall risk of bias, respectively (see Table 1). The risk of bias was low in 26 studies (50%) 
concerning random sequence generation; in 13 studies (25%) concerning allocation 
concealment; in no study concerning blinding of participants and personnel; in 18 studies 
(34.6%) concerning blinding of outcome assessment; in seven studies (13.5%) concerning 
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attrition bias; in 11 studies (21.1%) concerning selective reporting; in six studies (11.5%) 
concerning researchers’ alliance; and in 41 studies (78.8%) concerning other bias.  
 
Primary outcome: positive symptoms 
 
Figure 2 shows the network of treatments for the primary outcome. Two studies were not 
considered in the analyses, because they were not connected to the rest of the network, 
contributing neither direct nor indirect evidence29,68.  
Network meta-analysis results show that, for the primary outcome, CBT was associated 
with a higher decrease in positive symptoms than inactive control (SMD=–0.29; 95% CI: –
0.55 to –0.03, seven RCTs contributing direct evidence to the network meta-analysis, low 
confidence in the estimates), treatment as usual (SMD=–0.30; 95% CI: –0.45 to  –0.14, 18 
RCTs contributing direct evidence, moderate confidence in the estimates)  and supportive 
therapy (SMD=–0.47; 95% CI: –0.91 to  –0.03, two RCTs contributing direct evidence, low 
confidence in the estimates). The difference was not significant for the comparison with 
waitlist (SMD=–0.24; 95% CI: –0.65 to 0.16), but only two small trials (with 30 and 45 
participants respectively43,44) contributed direct evidence to this comparison (Figure 3). 
One study on hallucination focused integrative treatment showed a decrease in 
symptoms in comparison to treatment as usual and supportive therapy (moderate and low 
confidence in the estimate, respectively). All other relative treatment effects were very 
imprecise, but on average they favored the active psychological treatment over the inactive 
control interventions.  
The heterogeneity variance (tau2) was 0.0514, hence considered to be low to 
moderate23. The design-by-treatment interaction test did not reveal significant inconsistency 
(p=0.35). By splitting direct and indirect evidence for each comparison, we found no evidence 
for disagreement between these two pieces of evidence for any of the comparisons. None of 
the methods we used suggested important inconsistency but, given the low number of 
studies for most of the comparisons, the power of these tests is low. The assessments of 
confidence in the estimates using CINeMA highlighted moderate to very low confidence, 
primarily due to study limitations (high risk of bias) and imprecision. 
The interpretation of subgroup analyses is limited due to restricted number of studies 
available for the different subgroups. We did not detect any important indication that the 
advantage of CBT over treatment as usual is moderated by number of sessions, study 
duration, setting (individual vs. group), therapist’s expertise and severity at baseline.  
Similarly, exclusion of studies for the different sensitivity analyses left a low number of 
trials for most of the treatments. When excluding open label studies, results of CBT 
compared to treatment as usual and supportive therapy were consistent with the main 
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analysis (SMD=–0.27; 95% CI: –0.41 to –0.13 and SMD=–0.47; 95% CI: –0.86 to –0.08, 
respectively), while the difference between CBT and inactive control was not significant 
anymore (SMD=–0.14; 95% CI: –0.37 to 0.09). 
Sensitivity analyses excluding studies presenting only completer analyses, studies with 
high risk of bias, studies at high risk of bias for researchers’ allegiance, or studies focused on 
treatment resistant patients were overall consistent with the main analyses. 
The results of a post-hoc sensitivity analysis pooling the “active control” comparators did 
not differ from the main analysis.  
Investigation of small study effect and publication bias with conventional funnel plot did 
not reveal any association between study precision and effect size (only possible for CBT 
versus treatment as usual). However, the comparison-adjusted funnel plot suggests that 
small studies that did not show a benefit for the newer psychological treatment over the older 
treatment are underrepresented in our data (i.e., they possibly remain unpublished).  
 
Secondary outcomes 
 
CBT and inactive control were less acceptable than treatment as usual in terms of all-
cause discontinuation. All treatments had fewer dropouts than social skills training (with the 
exception of AVATAR therapy, acceptance and commitment therapy, and supportive 
therapy) (Figure 3).  
CBT was associated with a higher reduction of overall symptoms compared to waitlist 
and treatment as usual, and with higher reduction in negative symptoms compared with 
treatment as usual (Figure 4). Hallucination focused integrative treatment and CBT were 
associated with larger probability of response compared with treatment as usual and inactive 
control.  
When looking at adherence and insight, metacognitive training, social skills training, CBT 
and treatment as usual produced a higher improvement in comparison to supportive therapy. 
For quality of life and functioning, CBT was more efficacious than treatment as usual. No 
significant differences were observed for depression. Mortality was in general a rare event, 
and did not differ between treatments. Very few data were available for relapse, adverse 
events and other mortality outcomes.  
Heterogeneity variance assessed with tau2 ranged from 0 to 0.0649, being evaluated 
from none to low-to-moderate. The design-by-treatment interaction model revealed some 
inconsistency for the secondary outcome of depression (p=0.03).  
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DISCUSSION  
 
To our knowledge, this is the first network meta-analysis on psychological treatments for 
patients with positive symptoms of schizophrenia.  
With 40 studies, CBT was the most represented among the included treatments. We 
found significant efficacy for CBT in comparison with treatment as usual in many outcomes 
(positive, overall and negative symptoms, response to treatment, quality of life and 
functioning), higher efficacy in comparison with inactive control for positive symptoms and 
response to treatment, and in comparison with supportive therapy for adherence. There was 
no convincing proof of efficacy of other treatments, probably due to the small number of 
studies. 
CBT was also associated with higher dropout rates than treatment as usual (18.8% 
versus 12%). CBT might actually be less acceptable, and not all patients might be willing to 
engage in such a demanding treatment; however, we argue that to compare the dropout 
rates with those in treatment as usual could be misleading. Patients in this latter arm – by 
definition – continue their usual care, and they might have less reason to leave in 
comparison with patients assigned to a new intervention, that they could find demanding or 
challenging, or about which they may have high expectations, being discouraged if they do 
not see results in a few sessions. As a confirmation to this hypothesis, the inactive control 
condition (where patients participate to sessions like befriending and recreation activities) 
also had a higher dropout rate than treatment as usual.  
Patients in the included studies were only moderately ill on the average, compared with 
those in a meta-analysis of studies testing antipsychotic drugs vs. placebo, where they were 
markedly ill82. It seems that severely ill patients are usually not enrolled in psychotherapy 
studies. But this finding just reflects clinical practice: psychotherapy requires a minimum 
ability of patients to collaborate, and many patients do not have this ability when they are 
very acutely ill.  
Interpretation of subgroup and sensitivity analyses was limited by the low number of 
studies available. However, results on CBT remained stable after all pre-planned sensitivity 
analyses, corroborating the robustness of the results for this intervention. We also tested the 
potential role of researchers’ allegiance18, by excluding the studies in which the authors 
tested the efficacy of an intervention that was developed by themselves, and did not find 
significantly different results from the main analysis.  
One open and increasingly relevant issue is whether psychological interventions might 
cause harm15. We collected all the available data about adverse events potentially connected 
with the psychological intervention, but we found this aspect very poorly reported in the trials. 
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We believe that future studies should collect and report this information, in order to address 
this still unclear question83. 
Our results are in agreement with findings from some previous pairwise meta-analyses, 
where CBT was found to be efficacious for overall, positive and negative symptoms of 
schizophrenia in comparison with control conditions4-6, but not when compared with other 
psychological therapies7. However, the results of previous studies and reviews regarding the 
efficacy of CBT for schizophrenia have been conflicting.  
In this context, the role of blinded studies may be particularly critical8. Here, our results 
are in contrast with the findings of Jauhar et al6: when excluding studies with a non-blind 
outcome assessor, they found no differences between CBT and any control condition. On the 
contrary, we found that the superiority for CBT over treatment as usual and inactive control 
was maintained also in blinded studies. It was not maintained over supportive therapy and 
waiting list, but only very few studies (two and one, respectively) contributed direct evidence 
for these comparators.  
However, our work cannot be directly compared with that of Jauhar et al6, because they 
included any patients with schizophrenia without a restriction to positive symptoms, they 
used somewhat different criteria for risk of bias, and they lumped all comparators together in 
their pairwise meta-analysis.  
Our findings have the following limitations. First, available data for other treatments than 
CBT and for CBT versus other nodes than treatment as usual are based on few studies only, 
leading to low power to detect possible differences. Therefore, results should be interpreted 
with caution, in particular when looking at sensitivity and subgroup analyses. For this reason 
we did not focus our interpretation on hierarchies (SUCRA rankings), that could be 
misleading when there are no statistically significant differences among active treatments.  
Second, our focus was on the treatment of positive symptoms, and the findings observed 
for other outcomes might be secondary to the effect of the treatment on these symptoms. For 
example, a patient might experience withdrawal, lack of spontaneity, depressive symptoms 
or a lower functioning due to the difficulties connected with delusions or hallucinations. When 
these are treated, the quality of life and the other symptoms may benefit as well. For this 
reason, we focus our interpretations mainly on positive symptoms.  
Third, patients in the included trials were also receiving antipsychotic medication. We 
collected the available information on the use of antipsychotics. However, this was rarely 
given and never provided for experimental and control arm separately. The only exception is 
the study of Morrison et al65, that included patients not receiving antipsychotic medication (a 
post-hoc sensitivity analysis excluding this study did not materially change the results). As a 
result, it was not possible to assess the role of pharmacological treatment as a moderator. 
However, we assume that the intake of medications can be considered similar across study 
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arms, due to randomization. Furthermore, we argue that the situation in the included studies 
resembles what happens in real-life clinical practice, where psychological interventions are 
intended to be used as add-on to pharmacological therapy, and participants usually continue 
their previous medication. 
On the other hand, this work presents outstanding strengths. First, the study was 
carefully planned in agreements with PRISMA guidelines, and followed a sound methodology 
that was a priori published in the protocol3. This included comprehensive outcome measures 
and the evaluation of quality at study level (risk of bias) and confidence in results at outcome 
level (CINeMA). Second, the consideration of control conditions such as treatment as usual 
and waiting list as separate allowed to ascertain their relative efficacy. This is particularly 
important, as waitlist has been found to be connected with a nocebo effect83. Third, the strict 
selection criteria led to a homogenous population, as confirmed by very low heterogeneity, 
coherence across direct and indirect comparisons, and by side-splitting test and design-by-
treatment interaction test. This makes us confident that the results of this study are robust.  
In conclusion, cognitive behavior therapy seems to be effective on positive symptoms in 
moderately ill patients with schizophrenia, with effect sizes in the lower to medium range, 
depending on the control condition. 
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Figure 1  PRISMA flow chart of the study selection process  
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Table 1  Characteristics of studies 
 
Study Country Treatments (N  
patients) 
Trial 
duration 
(weeks) 
N sessions Diagnosis Study 
design 
 
Risk of bias 
(overall) 
Barrowclough et al 
(28) 
UK Cognitive behavioural 
therapy (N=57), TAU 
(N=56) 
26 10.4 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Bechdolf et al (29) Germany Cognitive behavioural 
therapy (N=40), 
psychoeducation (N=48) 
8 11.9 (cognitive 
behavioural 
therapy), 6.4 
(psychoeducation) 
Episode of a 
schizophrenic or related 
disorder 
(ICD-10) 
SB High 
Birchwood et al (30) UK Cognitive behavioural 
therapy (N=98), TAU 
(N=99) 
39 19 Schizophrenia or 
schizoaffective disorder  
(ICD-10) 
SB Moderate 
Drury et al (31) UK Cognitive therapy 
(N=30), recreation and 
support (N= 32) 
12 NA Functional psychosis 
(DSM-IV) 
OL High 
Durham et al (32) UK Cognitive behavioural 
therapy (N=22), 
supportive therapy 
(N=23), TAU (N=21) 
39 20 Schizophrenia, 
schizoaffective disorder 
or delusional disorder 
(ICD-10 and DSM-IV) 
SB High 
England (33) NA (author’s 
affiliation in 
Canada) 
Cognitive nursing 
intervention (N=44), 
TAU (N=21) 
18 12 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Foster et al (34) UK Cognitive behavioural 
therapy (N=12), TAU 
(N=12) 
4 4 Schizophrenia, 
schizoaffective disorder 
or delusional disorder 
(clinical diagnosis) 
OL High 
Freeman et al (35) UK Cognitive behavioural 
therapy (N=15), TAU 
(N=15) 
8 6 Schizophrenia, 
schizoaffective disorder 
or delusional disorder 
(clinical diagnosis) 
SB Low 
Freeman et al (36) UK Cognitive behavioural 
therapy (N=73), TAU 
(N=77) 
8 5.5 Schizophrenia, 
schizoaffective disorder 
or delusional disorder 
(clinical diagnosis) 
SB High 
Freeman et al (37) UK Cognitive behavioural 
therapy (N=24), TAU 
(N=26) 
12 7.3 Schizophrenia, 
schizoaffective disorder 
or delusional disorder 
(clinical diagnosis) 
SB Moderate 
Garety et al (38) UK Cognitive behavioural 
therapy (N=27), family 
intervention (N=28), 
39 13.9 Non-affective psychosis 
(DSM-IV and ICD–10) 
SB Moderate 
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TAU (N=28) 
Garety et al (38) UK Cognitive behavioural 
therapy (N=106), TAU 
(N=112) 
39 14.3 Non-affective psychosis 
(DSM-IV and ICD–10) 
SB Moderate 
Gottlieb et al (39) US Cognitive behavioural 
therapy (N=19), TAU 
(N=18) 
24 10 Schizophrenia, 
schizoaffective disorder 
or psychosis not 
otherwise specified  
(NA) 
SB Moderate 
Habib et al (40) Pakistan Cognitive behavioural 
therapy (N=21), TAU 
(N=21) 
21 13 Schizophrenia 
(DSM-IV-TR)  
SB High 
Haddock et al (41) UK Cognitive behavioural 
therapy (N=10), 
supportive counselling 
(N=11) 
5 10.2 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Haddock et al (42) UK Cognitive behavioural 
therapy (N=38), social 
activity therapy (N=39) 
26 17 (Cognitive 
Behavioural 
Therapy), 17.4 
(Social Activity 
Therapy) 
Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Hazell et al (43) UK Cognitive behavioural 
therapy (N=15), waitlist 
(N=15) 
12 8 Schizophrenia and 
related disorders (NA) 
SB Moderate 
Krakvik et al (44) Norway Cognitive behavioural 
therapy (N=23), waitlist 
(N=22) 
26 20 Schizophrenia, 
schizoaffective disorder 
or persistent delusional 
disorder 
(ICD-10) 
OL Moderate 
Kuipers et al (45) UK Cognitive behavioural 
therapy (N=28), TAU 
(N=32) 
39 18.6 Paranoid schizophrenia 
(DSM-III-R) 
OL High 
Lecomte et al (46) Canada Cognitive behavioural 
therapy (N=48), social 
skills training (N=54), 
waitlist (N=27) 
13 24 Schizophrenia spectrum 
disorder 
SB Moderate 
Lee et al (47) South Korea Cognitive behavioural 
social skills training 
(N=12), TAU (N=13) 
7 12 Schizophrenia 
(DSM-IV-TR) 
SB Moderate 
Lee et al (48) South Korea Cognitive behavioural 
therapy (N=25), 
supportive therapy 
(N=25) 
32 20.1 Schizophrenia (DSM-
IV) 
SB Moderate 
Levine et al (49) NA (author’s 
affiliation in 
Israel) 
Cognitive therapy (N=6), 
supportive therapy 
(N=6) 
6 6 Paranoid schizophrenia 
(DSM-III-R) 
NA High 
Li et al (50) China Cognitive behavioural 
therapy (N=96), 
24 15 Schizophrenia (DSM-
IV) 
SB Moderate 
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supportive therapy 
(N=96) 
McLeod et al (51) UK Cognitive behavioural 
therapy (N=10), waitlist 
(N=10) 
12 8 Schizophrenia (DSM-
IV) 
NA High 
Morrison et al (52) UK Cognitive therapy 
(N=37), TAU (N=37) 
39 13.3 Schizophrenia, 
schizoaﬀective disorder 
or delusional disorder 
(ICD-10 or PANSS) 
 
SB Moderate 
Penn et al (53) US Cognitive behavioural 
therapy (N=32), 
supportive therapy 
(N=33) 
12 8.3 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Low 
Pinninti et al (54) US Cognitive behavioural 
therapy (N=18), TAU 
(N=15) 
12 11.93 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Pot-Kolder et al (55) The 
Netherlands 
Virtual reality based 
cognitive behavioural 
therapy (N=58), waitlist 
(N=58) 
12 16 Psychotic disorder 
(DSM-IV) 
SB Low 
Rector et al (56) Canada Cognitive behavioural 
therapy (N=24), TAU 
(N=21) 
26 20 Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB Moderate 
Sensky et al (57) UK Cognitive behavioural 
therapy (N=46), 
befriending (N=44) 
39 19 Schizophrenia 
(ICD-10 Research 
Criteria and DSM-IV) 
SB Moderate 
Startup et al (58) UK Cognitive behavioural 
therapy (N=47), TAU 
(N=43) 
26 12.9 Schizophrenia, 
schizophreniform 
disorder or 
schizoaffective disorder 
(DSM-IV) 
OL High 
Tarrier et al (59) UK Cognitive behavioural 
therapy (N=33), 
supportive Counselling 
(N=26), TAU (N=28) 
10 20 Schizophrenia, 
schizoaffective 
psychosis or delusional 
disorder 
(DSM-III-R) 
SB Moderate 
Trower et al (60) UK Cognitive behavioural 
therapy (N=18), TAU 
(N=20) 
26 16 Schizophrenia or related 
disorder 
(ICD-10) 
SB High 
Turkington et al (61) UK Cognitive behavioural 
therapy (N=13), 
befriending (N=6) 
8 6 Schizophrenia (ICD-10 
Research Criteria) 
SB Moderate 
Valmaggia et al (62) The 
Netherlands, 
Belgium 
Cognitive behavioural 
therapy (N=36), 
supportive counselling 
(N=26) 
23 16 Schizophrenia (DSM-
IV) 
SB Moderate 
van der Gaag et al The Cognitive behavioural 26 13 Schizophrenia or SB High 
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(63) Netherlands therapy (N=110), TAU 
(N=106) 
schizoaffective disorder 
(DSM-IV-TR) 
Velligan et al (64) US Cognitive behavioural 
therapy (N=43), 
cognitive adaptation 
training (N=41), 
cognitive behavioural 
therapy + cognitive 
adaptation training 
(N=40), TAU (N=42) 
39 26.6 (cognitive 
behavioural 
therapy), 27.5 
(cognitive 
adaptation training), 
27.5 (cognitive 
behavioural therapy 
+ cognitive 
adaptation training) 
Schizophrenia or 
schizoaffective disorder 
(DSM-IV) 
SB High 
Wahass & Kent (65) Saudi Arabia Cognitive behavioural 
therapy (N=3), TAU 
(N=3) 
9 25 Schizophrenia (ICD-10) OL Moderate 
Wittorf et al (66) Germany Cognitive behavioural 
therapy (N=50), 
supportive therapy 
(N=50) 
33 20 Schizophrenia, 
schizophreniform 
disorder, schizoaffective 
disorder or delusional 
disorder 
(DSM-IV) 
SB High 
Wykes et al (67) UK Cognitive behavioural 
therapy (N=45), TAU 
(N=40) 
10 7 Schizophrenia (DSM-
IV) 
OL High 
ACTRN12616000976
482 (68) 
Australia Metacognitive training 
(N=28), cognitive 
remediation (N=28) 
4 4 Schizophrenia spectrum 
disorder (DSM-V) 
SB Moderate 
Briki et al (69) France Metacognitive training 
(N=35), supportive 
therapy (N=33) 
8 14.6 Schizophrenia or 
schizoaffective disorders 
(DSM-IV-TR) 
SB High 
Favrod et al (70) Switzerland Metacognitive training 
(N=26), TAU (N=26) 
8 7 Schizophrenia spectrum 
disorder 
(ICD-10) 
SB Moderate 
Kumar et al (71) India Metacognitive training 
(N=8), TAU (N=8) 
4 8 Paranoid schizophrenia 
(ICD-10) 
NA High 
So et al (72) Hong Kong Metacognitive training 
(N=23), waitlist (N=21) 
4 3.15 Schizophrenia spectrum 
disorder 
(clinical diagnosis) 
SB Moderate 
van Oosterhout et al 
(73) 
The 
Netherlands 
Metacognitive training 
(N=75), TAU (N=79) 
8 8 Psychotic disorder in the 
DSM-IV schizophrenia 
spectrum 
(DSM-IV-TR) 
SB Moderate 
Chadwick et al (74) UK Mindfulness (N=11), 
waitlist (N=11) 
10 10 Psychotic disorder  
(NA) 
OL High 
Chadwick et al (75) UK Mindfulness (N=54), 
TAU (N=54) 
16 12 Schizophrenia or 
schizoaffective disorder  
(ICD-10) 
SB Low 
Bach & Hayes (76) US Acceptance and 
Commitment therapy 
16 4 Auditory hallucinations 
or delusions (clinical 
OL High 
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(N=40), TAU (N=40) diagnosis) (81.25% 
diagnosed with 
schizophrenia, 
schizoaffective disorder 
or delusional disorder) 
Shawyer et al (77) Australia Acceptance and 
commitment therapy 
(N=49), befriending 
(N=47) 
13 7 Schizophrenia or 
schizoaffective disorder 
(DSM-IV-TR) 
SB Low 
Schnackenberg et al 
(78) 
Germany Experienced focused 
counselling (N=12), 
TAU (N=10) 
44 NA Schizophrenia and 
schizoaffective disorder 
(NA) 
OL High 
Jenner et al (79) The 
Netherlands 
Hallucination focused 
integrative treatment 
(N=39), TAU (N=39) 
39 11 Non affective psychosis, 
including schizophrenia, 
schizoaffective or 
psychotic disorder not 
otherwise specified  
(DSM-IV) 
OL High 
Craig et al (80) UK AVATAR therapy (N= 
75), supportive 
counselling (N=75) 
12 5.6 (AVATAR 
therapy), 5.1 
(supportive 
counselling) 
Schizophrenia spectrum 
disorder or affective 
disorder with psychotic 
symptoms 
(ICD-10) 
SB Low 
 
TAU – treatment as usual, OL – open label, SB – single blind, NA – not available, PANSS – Positive and Negative Syndrome Scale 
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Figure 2  Network meta-analysis of eligible comparisons for positive symptoms. Line width is proportional to the number of trials comparing every pair of 
treatments. Node size is proportional to the number of studies providing data for each treatment  
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HFIT 
NMA 0.60  
 (0.10;  3.58) 
NMA 0.53  
 (0.09;  3.01) 
NMA 0.48  
 (0.08;  2.97) 
NMA 0.48  
 (0.07;  3.20) 
NMA 0.40  
 (0.08;  1.94); 
PWA 0.40  (0.08;  
1.94) 
NMA 0.39  
 (0.07;  2.29) 
NMA 0.32  
 (0.06;  1.88) 
NMA 0.31  
 (0.05;  1.82) 
NMA 0.30  
 (0.06;  1.47) 
NMA 0.28  
 (0.05;  1.39) 
NMA 0.27  
 (0.05;  1.40) 
NMA 0.11  
 (0.02;  0.66) 
HFIT MF 
NMA 0.88  
 (0.30;  2.61) 
NMA 0.80  
 (0.23;  2.79) 
NMA 0.80  
 (0.21;  3.09) 
NMA 0.67 (0.29;  
1.56); PWA 0.67  
(0.25;  1.74) 
NMA 0.66 (0.24;  
1.79); PWA 0.67  
(0.14;  3.24) 
NMA 0.54  
 (0.17;  1.70) 
NMA 0.51  
 (0.16;  1.67) 
NMA 0.50  
 (0.21;  1.19) 
NMA 0.46  
 (0.19;  1.15) 
NMA 0.45  
 (0.17;  1.19) 
NMA 0.19  
 (0.07;  0.56) 
NMA -0.31       
 (-1.23;  0.61) 
AVATAR MT 
NMA 0.91  
 (0.28;  2.93) 
NMA 0.91  
 (0.25;  3.27) 
NMA 0.76 (0.36;  
1.58); PWA 0.78  
(0.34;  1.78) 
NMA 0.75 (0.30;  
1.85); PWA 0.68  
(0.17;  2.71) 
NMA 0.61  
 (0.21;  1.78) 
NMA 0.58  
 (0.19;  1.75) 
NMA 0.56  
 (0.26;  1.20) 
NMA 0.52  
 (0.23;  1.17) 
NMA 0.51  
 (0.21;  1.23) 
NMA 0.22  
 (0.08;  0.58) 
NMA -0.40  
 (-1·07;  0·28) 
NMA -0.09  
 (-0.71;  0.54) 
CBT EFT 
NMA 1.00   
 (0.25;  4.03) 
NMA 0.83 (0.33;  
2.08); PWA 0.83  
(0.33;  2.08) 
NMA 0.82  
 (0.25;  2.72) 
NMA 0.67  
 (0.20;  2.24) 
NMA 0.64  
 (0.19;  2.19) 
NMA 0.62  
 (0.24;  1.59) 
NMA 0.57  
 (0.22;  1.53) 
NMA 0.56  
 (0.20;  1.58) 
NMA 0.24  
 (0.07;  0.78) 
NMA -0.47  
 (-1.21;  0.28) 
NMA -0.15  
 (-0.88;  0.57) 
NMA -0.07  
 (-0.44;  0.30) 
MT FI 
NMA 0.84 (0.29;  
2.41); PWA 0.80  
(0.24;  2.67) 
NMA 0.82  
 (0.22;  3.02) 
NMA 0.67  
 (0.18;  2.46) 
NMA 0.64  
 (0.17;  2.43) 
NMA 0.62 (0.22;  
1.78); PWA 0.64  
(0.20;  2.03) 
NMA 0.58  
 (0.19;  1.72) 
NMA 0.56  
 (0.18;  1.76) 
NMA 0.24  
 (0.07;  0.86) 
NMA -0.46  
 (-1.86;  0.94) 
NMA -0.15  
 (-1.54;  1.25) 
NMA -0.06  
 (-1.31;  1.19) 
NMA 0.01  
 (-1.28;  1.29) 
EFC TAU 
NMA 0.98  
 (0.45;  2.14) 
NMA 0.80  
 (0.37;  1.77) 
NMA 0.77 (0.34;  
1.75); PWA 1.00  
(0.31;  3.19) 
NMA 0.74 (0.58;  
0.95); PWA 0.76  
(0.58;  0.98) 
NMA 0.69 (0.48;  
0.99); PWA 0.49  
(0.27;  0.91) 
NMA 0.67 (0.40;  
1.11); PWA 0.44  
(0.09;  2.02) 
NMA 0.29  
 (0.13;  0.62) 
NMA -0.55 
 (-1.46;  0.36) 
NMA -0.24  
 (-1.13;  0.65) 
NMA -0.15  
 (-0.79;  0.48); 
PWA -0.11  
 (-0.84;  0.63) 
NMA -0.09  
 (-0.81;  0.64) 
NMA -0.09  
 (-1.48;  1.29) 
FI WL 
NMA 0.82  
 (0.28;  2.41) 
NMA 0.78  
 (0.25;  2.39) 
NMA 0.75 (0.35;  
1.63); PWA 0.73  
(0.27;  1.95) 
NMA 0.70  
 (0.31;  1.59) 
NMA 0.68  
 (0.28;  1.66) 
NMA 0.29 (0.13;  
0.65); PWA 0.38  
(0.15;  1.00) 
NMA -0.57  
 (-1.41;  0.28) 
NMA -0.25  
 (-1.08;  0.57) 
NMA -0.17  
 (-0.71;  0.38) 
NMA -0.10  
 (-0.72;  0.52) 
NMA -0.11  
 (-1.45;  1.24) 
NMA -0.02  
 (-0.84;  0.81) 
MF AVATAR 
NMA 0.95  
 (0.32;  2.81) 
NMA 0.92  
 (0.43;  1.97) 
NMA 0.86 (0.43;  
1.73); PWA 0.86  
(0.43;  1.73) 
NMA 0.83  
 (0.34;  2.02) 
NMA 0.36  
 (0.12;  1.03) 
NMA -0.60  
 (-1.47;  0.27) 
NMA -0.29  
 (-1.12;  0.54) 
NMA -0.21  
 (-0.75;  0.34); 
PWA -0.10  
 (-0.69;  0.49) 
NMA -0.14  
 (-0.77;  0.50) 
NMA -0.15  
 (-1.50;  1.21) 
NMA -0.05  
 (-0.89;  0.78) 
NMA -0.04  
 (-0.78;  0.71) 
SST ACT 
NMA 0.97  
 (0.42;  2.22) 
NMA 0.90 (0.39;  
205); PWA 1.15  
(0.38;  3.52) 
NMA 0.87  
 (0.34;  2.24) 
NMA 0.37  
 (0.12;  1.13) 
NMA -0.64  
 (-1.42;  0.14) 
NMA -0.33 
 (-1.07;  0.41) 
NMA -0.24  
 (-0.65;  0.16); 
PWA -0.40  
 (-0.90;  0.09) 
NMA -0.18  
 (-0.64;  0.29); 
PWA 0.28  
 (-0.46;  1.02) 
NMA -0.18 
 (-1.49;  1.12) 
NMA -0.09  
 (-0.84;  0.66) 
NMA -0.07  
 (-0.68;  0.53); 
PWA -0.26  
 (-1.29;  0.77) 
NMA -0.04  
 (-0.61;  0.53); 
PWA 0.10  
 (-0.54;  0.74) 
WL CBT 
NMA 0.93 (0.69;  
1.25); PWA 0.94  
(0.69; 1.27) 
NMA 0.90 (0.57;  
1.42); PWA 0.92  
(0.58;  1.47) 
NMA 0.39 (0.18;  
0.81); PWA 0.32  
(0.14;  0.73) 
NMA -0.69  
 (-1.41;  0.03) 
NMA -0.38  
 (-0.95;  0.19); 
PWA -0.38  
 (-0.95;  0.19) 
NMA -0.29  
 (-0.55; -0.03); 
PWA -0.34  
 (-0.60; -0.07) 
NMA -0.22  
 (-0.67;  0.22) 
NMA -0.23  
 (-1.50;  1.04) 
NMA -0.14  
 (-0.82;  0.54) 
NMA -0.12  
 (-0.72;  0.48) 
NMA -0.09  
 (-0.69;  0.52) 
NMA -0.05  
 (-0.53;  0.43) 
IC IC 
NMA 0.97  
 (0.57;  1.66) 
NMA 0.42  
 (0.19;  0.92) 
NMA -0.69  
 (-1.35; -0.04); 
PWA -0.69  
 (-1.35; -0.04) 
NMA -0.38  
 (-1.02;  0.26) 
NMA -0.30  
 (-0.45; -0.14); 
PWA -0.28  
 (-0.44; -0.12) 
NMA -0.23  
 (-0.58;  0.12); 
PWA -0.30  
 (-0.72;  0.13) 
NMA -0.24  
 (-1.47;  1.00); 
PWA -0.24  
 (-1.47;  1.00) 
NMA -0.14  
 (-0.78;  0.49); 
PWA -0.10  
 (-0.82;  0.62) 
NMA -0.13  
 (-0.66;  0.40); 
PWA -0.06  
 (-0.67;  0.54) 
NMA -0.09  
 (-0.66;  0.47) 
NMA -0.05  
 (-0.47;  0.36) 
NMA -0.00  
 (-0.30;  0.29); 
PWA -0.41  
 (-1.11;  0.28) 
TAU ST 
NMA 0.43  
(0.18;  1.02 ) 
NMA -0.91  
 (-1.85;  0.02) 
NMA -0.60  
 (-1.43;  0.22) 
NMA -0.52  
 (-1.17;  0.14) 
NMA -0.45  
 (-1.19;  0.30) 
NMA -0.46  
 (-1.86;  0.95) 
NMA -0.36  
 (-1.27;  0.55) 
NMA -0.35  
 (-1.19;  0.50) 
NMA -0.31  
 (-1.16;  0.54) 
NMA -0.27  
 (-1.04;  0.49) 
NMA -0.22  
 (-0.82;  0.37); 
PWA -0.22  
 (-0.82;  0.37) 
NMA -0.22  
 (-0.89;  0.45) 
ACT SST 
NMA -0.87  
 (-1.66; -0.07) 
NMA -0.55  
 (-1.32;  0.21) 
NMA -0.47  
 (-0.91; -0.03); 
PWA -0.29  
 (-0.84;  0.26) 
NMA -0.40  
 (-0.88;  0.08); 
PWA -0.64  
 (-1.36;  0.08) 
NMA -0.41  
 (-1.72;  0.90) 
NMA -0.32  
 (-1.08;  0.45) 
NMA -0.30  
 (-0.98;  0.38) 
NMA -0.26  
 (-0.96;  0.43) 
NMA -0.23  
 (-0.80;  0.35) 
NMA -0.18  
 (-0.68;  0.33) 
NMA -0.17  
 (-0.61;  0.27); 
PWA -0.11  
 (-0.88;  0.67) 
NMA 0.05  
 (-0.74;  0.83) 
ST 
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                     Positive symptoms            Treatments                           Dropout                                Treatments 
 
Figure 3  Comparisons between psychological treatments for positive symptoms and study dropouts. Results for positive symptoms are presented in the lower triangle; results for 
dropout are presented in the upper triangle. Significant results are presented in bold. Relative treatments effects are measured by standardized mean difference (SMD) for  
positive symptoms and risk ratio (RR) for study dropout along with their 95% confidence intervals (95% CIs). SMDs lower than 0 and RRs lower than 1 favour the column 
defining treatment. SMDs of – 0.2 can be considered small, – 0.5 medium, and – 0.8 large. To obtain SMDs for comparisons in the opposite direction, negative values should be 
converted into positive values, and vice versa. To obtain RRs for comparisons in the opposite direction, reciprocals should be taken. ACT – acceptance and commitment therapy, 
CBT – cognitive behavioral therapy, EFC – experience focused counselling, FI – family intervention, HFIT – hallucination focused integrative treatment, IC – inactive control, 
MT – metacognitive training, MF – mindfulness, SST – social skills training, ST – supportive therapy, TAU – treatment as usual, WL – waitlist, NMA – network meta-analysis, 
PWA – pairwise meta-analysis  
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CBT 
NMA 0.05  
 (-0.40;  0.49) 
NMA 0.01  
 (-0.37;  0.39); 
PWA 0.08  
 (-0.32;  0.48) 
NMA -0.00  
 (-0.65;  0.65); 
PWA 0.00  
 (-0.65;  0.65) 
NMA -0.09  
 (-0.59;  0.41) 
NMA -0.09  
 (-0.26;  0.08); 
PWA -0.09  
 (-0.26;  0.08) 
NMA -0.12  
 (-0.48;  0.24); 
PWA -0.15  
 (-0.53;  0.22) 
NMA -0.16  
 (-0.80;  0.48) 
NMA -0.14  
 (-0.55;  0.26) 
NMA -0.18  
 (-0.69;  0.33); 
PWA -0.19  
 (-0.78;  0.41) 
NMA -0.16  
 (-0.29; -0.03); 
PWA -0.15  
 (-0.29; -0.02) 
HFIT ACT 
NMA -0.04  
 (-0.63;  0.55) 
NMA -0.05  
 (-0.84;  0.74) 
NMA -0.14  
 (-0.81;  0.53) 
NMA -0.14  
 (-0.55;  0.28); 
PWA -0.14  
 (-0.55;  0.28) 
NMA -0.16  
 (-0.74;  0.41) 
NMA -0.21  
 (-0.99;  0.57) 
NMA -0.19 
 (-0.74;  0.36) 
NMA -0.23  
 (-0.91;  0.44) 
NMA -0.21  
 (-0.67;  0.26) 
NMA -0.26  
 (-0.98;  0.46) 
CBT SST 
NMA -0.01  
 (-0.77;  0.75) 
NMA -0.10  
 (-0.73;  0.53) 
NMA -0.10  
 (-0.52;  0.32) 
NMA -0.13  
 (-0.55;  0.30); 
PWA 0.00  
 (-0.47;  0.47) 
NMA -0.17  
 (-0.88;  0.54) 
NMA -0.16  
 (-0.71;  0.40) 
NMA -0.19  
 (-0.83;  0.44) 
NMA -0.17  
 (-0.57;  0.23) 
NMA -0.10  
 (-1.55;  1.36) 
NMA 0.16  
 (-1.13;  1.45) 
EFC ST 
NMA -0.09  
 (-0.91;  0.73) 
NMA -0.09  
 (-0.76;  0.59) 
NMA -0.12  
 (-0.86;  0.63) 
NMA -0.16  
 (-1.08;  0.75) 
NMA -0.14  
 (-0.91;  0.62) 
NMA -0.18  
 (-1.01;  0.64) 
NMA -0.16  
 (-0.82;  0.51) 
NMA -0.42  
 (-1.35;  0.51) 
NMA -0.16  
 (-0.75;  0.43); 
PWA -0.08  
 (-0.71;  0.55) 
NMA -0.32  
 (-1.74;  1.10) 
SST HFIT 
NMA 0.00  
 (-0.52;  0.53) 
NMA -0.02  
 (-0.64;  0.59) 
NMA -0.07  
 (-0.87;  0.74) 
NMA -0.05  
 (-0.69;  0.59) 
NMA -0.09  
 (-0.79;  0.61) 
NMA -0.07  
 (-0.55;  0.41); 
PWA -0.07  
 (-0.55;  0.41) 
NMA -0.43  
 (-1.21;  0.34) 
NMA -0.17  
 (-0.46;  0.11); 
PWA -0.17  
 (-0.46;  0.11) 
NMA -0.34 
 (-1.66;  0.99) 
NMA -0.02  
 (-0.67;  0.64) 
IC IC 
NMA -0.03  
 (-0.43;  0.37) 
NMA -0.07  
 (-0.74;  0.59) 
NMA -0.06  
 (-0.42;  0.31); 
PWA -0.06  
 (-0.42;  0.31) 
NMA -0.10  
 (-0.63;  0.44) 
NMA -0.07  
 (-0.28;  0.14); 
PWA -0.12  
 (-0.70;  0.47) 
NMA -0.54  
 (-1.50;  0.43) 
NMA -0.28  
 (-0.94;  0.39); 
PWA -0·23  
 (-1.01;  0.54) 
NMA -0.44  
 (-1.88;  1.00) 
NMA -0.12  
 (-1.01;  0.77) 
NMA -0.10  
 (-0.83;  0.62) 
FI WL 
NMA -0.04  
 (-0.66;  0.57); 
PWA -0.19  
 (-0.94;  0.55) 
NMA -0.03  
 (-0.57;  0.51) 
NMA -0.07  
 (-0.69;  0.55) 
NMA -0.04  
 (-0.42;  0.34) 
NMA -0.59  
 (-1.60;  0.41) 
NMA -0.33 
 (-1.03;  0.37) 
NMA -0.49  
 (-1.96;  0.98) 
NMA -0.17  
 (-1.09;  0.74) 
NMA -0.16  
 (-0.80;  0.48); 
PWA -0.16  
 (-0.80;  0.48) 
NMA -0.06  
 (-1.02;  0.91) 
ACT MT 
NMA 0.02  
 (-0.74;  0.77) 
NMA -0.02  
 (-0.84;  0.79) 
NMA 0.00  
 (-0.64;  0.65) 
PWA -0.26  
 (-1.25;  0.73) 
NMA -0.59  
 (-1.47;  0.29) 
NMA -0.33  
 (-0.86;  0.20); 
PWA -0.28  
 (-0.85;  0.29) 
NMA -0.49  
 (-1.88;  0.90) 
NMA -0.17  
 (-0.96;  0.62) 
NMA -0.16  
 (-0.76;  0.45) 
NMA -0.05  
 (-0.90;  0.79) 
NMA 0.00  
 (-0.88;  0.88) 
ST AVATAR 
NMA -0.04  
 (-0.69;  0.61) 
NMA -0.01  
 (-0.44;  0.41) 
NMA -0.62  
 (-1.46;  0.21) 
NMA -0.36  
 (-0.80;  0.07); 
PWA -0.50  
 (-0.96; -0.05) 
NMA -0.53  
 (-1.89;  0.83) 
NMA -0.20  
 (-0.81;  0.40); 
PWA -0.10  
 (-0.78;  0.58) 
NMA -0.19  
 (-0.71;  0.33) 
NMA -0.09  
 (-0.88;  0.70) 
NMA -0.03  
 (-0.86;  0.79) 
NMA -0.03  
 (-0.72;  0.65) 
WL FI 
NMA 0.03  
 (-0.48;  0.53); 
PWA 0.02  
 (-0.56;  0.60) 
NMA -0.64  
 (-1.33;  0.06) 
PWA -0.64  
 (-1.33;  0.06) 
NMA -0.38  
 (-0.56; -0.20); 
PWA -0.36  
 (-0.54; -0.17) 
NMA -0.54  
 (-1.82;  0.74); 
PWA -0.54  
 (-1.82;  0.74) 
NMA -0.22  
 (-0.83;  0.40) 
NMA -0.20  
 (-0.54;  0.13) 
NMA -0.10  
 (-0.77;  0.56); 
PWA -0.06  
 (-0.82;  0.70) 
NMA -0.05  
 (-0.77;  0.68) 
NMA -0.05  
 (-0.59;  0.50); 
PWA 0.05  
 (-0.76;  0.86) 
NMA -0.01  
 (-0.48;  0.45) 
TAU TAU 
NMA -0.75  
 (-1.79;  0.29) 
NMA -0.49  
 (-1.26;  0.28) 
NMA -0.65  
 (-2.14;  0.84) 
NMA -0.33  
 (-1.24;  0.58) 
NMA -0.32  
 (-1.13;  0.50) 
NMA -0.21  
 (-1.22;  0.79) 
NMA -0.16  
 (-1.20;  0.88) 
NMA -0.16  
 (-1.09;  0.77) 
NMA -0.13  
 (-0.86;  0.61); 
PWA -0.69  
 (-1.61;  0.22) 
NMA -0.11  
 (-0.88;  0.66); 
PWA 0.77  
 (-0.37;  1.92) 
MT 
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 Overall symptoms  Treatments   Negative symptoms   Treatments 
Figure 4  Results for overall symptoms are presented in the lower triangle; results for negative symptoms are presented in the upper triangle. Significant results are presented in 
bold. Relative treatments effects are measured by standardized mean difference (SMD) along with its 95% confidence intervals (95% CIs). SMDs lower than 0 favour the column 
defining treatment. SMDs of – 0.2 can be considered small, – 0.5 medium, and – 0.8 large. To obtain SMDs for comparisons in the opposite direction, negative values should be 
converted into positive values, and vice versa. ACT – acceptance and commitment therapy, CBT – cognitive behavioral therapy, EFC – experience focused counselling, FI – 
family intervention, HFIT – hallucination focused integrative treatment, IC – inactive control, MT – metacognitive training, MF – mindfulness, SST – social skills training, ST – 
supportive therapy, TAU – treatment as usual, WL – waitlist, NMA – network meta-analysis, PWA – pairwise meta-analysis 
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